At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Datopotamab Deruxtecan (Dato-DXd) (drug), Durvalumab (drug)
- How long the study runs
- Study runs about 52 months (dates as stated)
- About the drug or intervention
- Datopotamab Deruxtecan (Dato-DXd) — drug: Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle. · Durvalumab — drug: Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at two ways of treating triple negative breast cancer that has spread and is PDL1-negative. It compares a drug called datopotamab deruxtecan taken on its own against datopotamab deruxtecan taken together with another drug called durvalumab. The study is for women aged 18 or over.
Who can take part
- Women aged 18 or over who can give written consent and follow the study plan
- Triple negative breast cancer (tests show the cancer is negative for ER, PR and HER2)
- The cancer is PDL1-negative (a test score called 22C3 CPS below 10)
- At least one tumour that can be measured on a scan, or certain bone lesions
- A tumour sample available for testing, or a tumour that can be biopsied
- Able to carry out day-to-day activities (performance status 0-1) with a life expectancy of at least 12 weeks
- Healthy enough blood, liver and kidney test results
- Not pregnant or breastfeeding, and willing to use contraception during and for 7 months after treatment
- Body weight over 30 kg
Who may not be able to
- Previous chemotherapy, immunotherapy (including durvalumab) or PARP inhibitor treatment for advanced or metastatic breast cancer
- Certain prior treatments (checkpoint inhibitors or targeted drugs) within 6 months
- Previous stem cell transplant or organ transplant
- Ongoing steroid treatment or certain immune system problems
- Live vaccines within 30 days before starting
- Active or past autoimmune or inflammatory conditions (with some exceptions)
- History of lung scarring or inflammation (pneumonitis or interstitial lung disease)
- Active infection, HIV, active hepatitis B or C, or tuberculosis
- Another cancer within the last 5 years (with some exceptions)
- Untreated or unstable brain metastases or spinal cord compression
- Pregnant or breastfeeding
- Certain heart rhythm problems (a long QT interval on heart traces)
- Severe allergies to monoclonal antibodies or study drugs
- Serious uncontrolled health problems, or taking part in another trial within 28 days
- Eye problems affecting the cornea
- Cancer spread to the lining of the brain and spinal cord
What taking part involves
- • Being given one of two treatments by chance: datopotamab deruxtecan on its own, or datopotamab deruxtecan plus durvalumab
- • Regular scans (CT or MRI) to measure the cancer
Time commitment: Not stated — ask the trial team about how many visits are needed, how long the study lasts, and what taking part involves day to day.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- Female
- Number of participants
- 140
- Started
- 2025-10-27
- Last checked
- 2026-05
Plain English Summary
What is this study?
- • Testing a new treatment for triple negative breast cancer
- • Phase2 - 140 participants
- • The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with triple negative breast cancer
- • Female only
Where?
- • London - Barts Cancer Institute, Centre of Experimental Cancer Medicine
- • London - Barts Health NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). Globally, breast cancer is the most common malignancy in women and the second most common cancer overall. The term TNBC is used to define tumours that do not express oestrogen receptors, progesterone receptors and HER2 receptors. TNBC comprises 10 -15% of all breast cancers. It remains the subtype with poorest outcome and there is a significant need to develop new therapies for this group of patients especially. Moreover, the PDL1-negative tumour has demonstrated no benefit from standard 1st line treatment of chemotherapy plus immune checkpoint inhibitors.
More detail
The aim of this study is to demonstrate the superiority of Datopotamab deruxtecan (Dato-DXd) plus Durvalumab (Durvalumab) relative to Dato-DXd alone in patients with PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). This is also the primary endpoint of this study and effectivenss measured by progression-free survival. Dato-DXd is an antibody drug conjugate (ADC) that targets tumour-associated calcium signal transducer 2, TROP2, a transmembrane protein that is highly expressed in various epithelial tumors including breast cancer. Durvalumab is an immune checkpoint inhibitor and is expected to stimulate the patient's anti-tumour immune response by binding to PD-L1 and shifting the balance toward an anti-tumour response. The preclinical and clinical evidence have suggested synergistic activity between antibody drug conjugate and immune checkpoint inhibitor. This study will recruit 140 patients, aged 18 and over and consenting patients will be randomly placed into one of two treatment groups. One group will receive Datopotamab deruxtecan in combination with Durvalumab and the other groups will receive Datopotamab deruxtecan alone. Treatment will continue unless there is evidence of unacceptable toxicity, disease progression, or if the patient requests to stop the treatment or death. Safety and tolerability as well as progression free survival, overall survival, clinical benefit rate, duration of response and duration of clinical benefit and quality of life will be assessed. PD-L1 is part of a complex system of receptors and ligands that are involved in controlling T-cell activation. The PD-1 receptor (cluster of differentiation \[CD\]279) is expressed on the surface of activated T cells. It has 2 known ligands: programmed cell death ligand-1 (PD-L1; B7-H1; CD274) and programmed cell death ligand-2 (PD-L2; B7-DC; CD273). PD-L1/PD-L2 belong to a family of immune checkpoint proteins that act as coinhibitory factors, which can halt or limit the development of T cell response. When PD-L1 binds to PD-1, an inhibitory signal is transmitted into the T cell, which reduces cytokine production and suppresses T cell proliferation. Tumour cells exploit this immune checkpoint pathway as a mechanism to evade detection and inhibit immune response. Sites will perform local PD-L1 testing to confirm the PD-L1 status of potentially eligible patients. PD-L1 negativity in this trial will be defined as 22C3 Combined Positive Score (CPS) of less than 10. Durvalumab is a human mAb of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells. The proposed mechanism of action for durvalumab is interference in the interaction of PD-L1 with PD-1 and CD80 (B7.1). The blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, including those that may result in tumor elimination. In vitro studies demonstrate that durvalumab antagonizes the inhibitory effect of PD-L1 on primary human T cells, resulting in restored interferon-gamma (IFN-γ)-induced proliferation. In vivo studies have shown that durvalumab inhibits tumor growth in xenograft models via a T cell-dependent mechanism. Based on these data, durvalumab is expected to stimulate the patient's antitumor immune response by binding to PD-L1 and shifting the balance toward an antitumor response. Durvalumab has been engineered to reduce antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Dato-DXd is an antibody drug conjugate that targets tumour-associated calcium signal transducer 2, TROP2, a transmembrane protein that is highly expressed in various epithelial tumours including breast cancer. TROP2 has several binding partners, including claudin 1, claudin 7, cyclin D1, protein kinase C, phosphatidylinositol 4,5-bisphosphate, and insulin-like growth factor 1. By binding to these targets, TROP2 affects tight junctions at the epithelial barrier and increases tumour proliferation, podosome formation, and Raf and NF-kappa activation and suppresses IGF-1R signaling \[21,22\]. Its expression correlates with aggressive tumour behaviour and has been used as a prognostic marker in several types of cancer. DNA topoisomerase I is an enzyme that acts by causing a transient break in 1 strand of DNA. This enables the unwinding of positive or negative supercoiled DNA through a hindered rotary system, thus allowing the separation of the double-helix strands. This activity is prominent during cell replication. Inhibition of DNA topoisomerase I can lead to cell apoptosis following multiple breaks in the cell DNA. DNA topoisomerase I has therefore been identified as a potential target for cancer treatment. In order to overcome the challenges of delivering cytostatics specifically into cancer cells, ADCs have been developed. ADCs are composed of an antibody, a linker, and a cytotoxic agent. ADCs are payload delivery systems that can target cells that express the preferred marker. The ADC specifically binds and is internalized into the target cells, and enzymatic processes release the drug into the cytoplasm. Dato-DXd binds to TROP2, is internalized, and undergoes enzymatic processing. Thereafter the DNA Dato-DXd binds to TROP2, and after further enzymatic processing, the DNA topoisomerase I inhibitor DXdis released, inhibits cell replication, and promotes cell apoptosis. The anti-TROP2 component, is a humanized IgG1 kappa monoclonal antibody. The released drug is a DNA topoisomerase I inhibitor derivative of exatecan. The monoclonal antibody is covalently conjugated to a drug-linker, which is composed of a cleavable maleimide tetrapeptide linker and the released drug. The tetrapeptide linker is designed to be stable in plasma to reduce systemic exposure to the released drug. In vitro studies indicate that Dato-DXd exhibits TROP2 expression-dependent cell growth inhibitory activity, and in vivo studies using a tumor-bearing mouse model indicate that administration of Dato-DXd results in the regression of TROP2-positive tumors. The biodistribution and antitumor activity of the ADC are expected to depend on the expression level of the target antigen in tumor tissue.Dato-DXd has been evaluated in multiple solid tumors ,including NSCLC, and TNBC, HR+/HER2- BC, and urothelial cancer have high expression of TROP2, 1,2 and the DNA topoisomerase I inhibitor, irinotecan, shows clinical efficacy in these indications 9,10. Dato-DXd has shown preliminary efficacy in the ongoing clinical studies. The screening period for the trial is 28 days. Following randomisation, patients must commence on trial treatment within 3 days. There are specific protocol mandated pre-randomisation eligibility criteria that needs to be fulfilled, which includes the below: 1. Assessing eligibility thoroughly using the protocol inclusion and exclusion criteria and obtaining informed consent. 2. Conducting local PD-L1 assessment and confirming PD-L1 negativity by 22C3 Combined Positive Score (CPS) of less than 10. 3. A representative formalin-fixed, paraffin embedded (FFPE) tumour specimen with the supporting report is required to enable the definitive diagnosis of TNBC, with adequate viable tumour cells in a tissue block. 4. Obtaining medical history and demographics. 5. Confirming ECOG performance status. 6. Completing limited physical exam (including clinical breast examination), vital sins and weight with height. 7. Haematology and Biochemistry bloods. 8. Urinalysis. 9. Pregnancy test. 10. Thyroid function test. 11. Coagulation and Virology test. 12. Yearly ophthalmologic assessment if done as routine standard of care. 13. CT tumour assessment (using RECIST v1.1). 14. Brain scan. 15. Collection of adverse events and concomitant medications. 16. Completion of QOL questionnaires. 17. Collection if research blood samples. Once the above assessments have satisfactorily completed, the sponsor team, CECM DIAMOND coordinating team will check the screening eCRF data against the protocol and confirm eligibility. Once this has been completed, site staff can then proceed to randomising the patient on the Interactive Response Technology (IRT) system. Both the site and pharmacy staff and the CECM coordination team will receive a confirmation of randomisation via email. Patients will be randomised in 1:1 rations to receive one of the two following treatment arms: 1. Dato-DXd (Dose 6mg/kg, IV) plus Durvalumab (1120 mg, IV) on Day 1 Q3W. 2. Dato-DXd (Dose 6mg/kg) on Day 1 Q3W. Randomisation will be stratified as a three-part stratification by the following: 1. Is de novo; or 2. has treatment-free interval of \< = 12 months or 3. has a treatment-free interval of \> 12 months Throughout the duration of the trial treatment, the below assessments will be performed (+/- 3 days) and associated data collected and reported on the eCRF: 1. ECOG performance status. 2. Limited physical exam (including clinical breast examination), vital sins and weight with height. 3. Haematology and Biochemistry bloods. 4. Pregnancy test. 5. Thyroid function test. 6. CT tumour assessment (using RECIST v1.1) every 9 weeks until disease progression. 6\. Yearly ophthalmologic assessment if done as routine standard of care. 7. Adverse events and concomitant medications. 8. QOL questionnaires. 9. Patient review for safety occurring only on day 14 from cycle 1 to 3, where information on adverse events on concomitant medications will be collected. During the safety visit, which occurs 90 days after the last dose (+/- 7 days), the below assessments will be performed and associated data collected and reported on the eCRF: 1. ECOG performance status. 2. Limited physical exam (including clinical breast examination), vital sins and weight with height. 3. Haematology and Biochemistry bloods. 4. Pregnancy test. 5. Thyroid function test. 6. Ophthalmologic assessment if done as routine standard of care. 7. Adverse events and concomitant medications. 8. QOL questionnaires. Upon disease progression, the below assessments will be performed and associated data collected and reported on the eCRF: 1. CT tumour assessment (using RECIST v1.1). 2. Adverse events and concomitant medications. 3. Optional fresh tumour biopsy. 4. Research blood samples. When a patient discontinues study treatment, they will be followed up for subsequent anti-cancer therapies, disease and survival status until death, loss to follow-up or withdrawal of consent (whichever comes first) All patients will be followed up for survival until 2 year post last patient treatment discontinuation. Each patient will be followed up at least every 6 months in the follow up period. If patient requests to be withdrawn from follow-up; this request must be documented in the source documents and signed by the investigator. If the patient withdraws from study treatment but not from follow-up, the study staff may use patient medical records to obtain information about subsequent anti-cancer therapies.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: Female only
- How fit you need to be: ECOG 0 or better
Biomarkers mentioned
What the study is looking for
- ✓Willing and able to provide written agreement to take part.
- ✓Ability to comply with the protocol.
- ✓Female ≥ 18 years of age.
- ✓Triple-negative disease, defined as tumour cells being:
- ✓Negative for ER with \<10% of tumour cells positive for ER on IHC or IHC score (Allred) of ≤3.
Who cannot take part
- ✗Prior drug treatment, treatment that helps your immune system fight cancer (including durvalumab) or treatment with PARP inhibitors for advanced or...
- ✗Patients with prior allogeneic stem cell or solid organ transplantation.
- ✗Patients with vitiligo or alopecia
- ✗Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy
- ✗Any chronic skin condition that does not require treatment that goes through your whole body
See the full criteria
Where Is This Study? (2 UK sites)
Barts Cancer Institute, Centre of Experimental Cancer Medicine
London EC1M 6BQ, United Kingdom
Barts Health NHS Trust
London, United Kingdom
How to Get in Touch
Peter Schmid, MD PhD, FRCP
Sponsor contactCONTACT
